AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)), AstraZeneca plc ((GB:AZN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca, in collaboration with Parexel International, has completed a Phase I clinical study titled A Phase I, Randomised, Single-dose, Open-label, 3-period, 3-treatment, 3-way Crossover Study to Assess the Effect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics in Fed and Fasted State and Pharmacokinetics of Balcinrenone When Dosed With a P-gp Inhibitor in Healthy Participants. The study aimed to evaluate how food affects the pharmacokinetics of balcinrenone/dapagliflozin and the impact of a P-gp inhibitor on balcinrenone in healthy individuals.
The study tested the effects of balcinrenone/dapagliflozin, a combination drug, in different conditions: fasted, fed, and with the P-gp inhibitor quinidine. The goal was to understand how these variables influence drug absorption and processing in the body.
This interventional study was randomized and used a crossover model without masking, focusing on treatment as its primary purpose. Participants underwent three treatment sequences, each separated by a 72-hour washout period, to ensure accurate results.
The study began on May 20, 2025, and was last updated on August 11, 2025. These dates mark the study’s progression and completion, providing a timeline for stakeholders and investors.
The completion of this study could influence AstraZeneca’s stock performance positively, as it adds to the company’s portfolio of research and development. The results may also impact investor sentiment, particularly if the findings support further development of the drug combination. In the competitive pharmaceutical industry, such advancements can enhance a company’s market position.
The study is now completed, with further details available on the ClinicalTrials portal.